Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse (Q44689978)

5 December 2017

Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse (English)

1 reference

5 December 2017

myocardial infarction

1 reference

Margot C LaPointe

1

1 reference

5 December 2017

Mariela Mendez

2

1 reference

5 December 2017

Alicia Leung

3

1 reference

5 December 2017

Zhenyin Tao

4

1 reference

5 December 2017

Xiao-Ping Yang

5

1 reference

5 December 2017

language of work or name

1 reference

11 December 2003

1 reference

American Journal of Physiology Heart and Circulatory Physiology

5 December 2017

1 reference

5 December 2017

286

1 reference

5 December 2017

4

1 reference

5 December 2017

H1416-24

1 reference

Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities

5 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Influence of sulfinpyrazone and naproxen on infarct size in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Lack of effect of aspirin on myocardial infarct size in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Role of prostacyclin in the cardiovascular response to thromboxane A2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Spreading depression-induced cyclooxygenase-2 expression in the cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Trophic effects of the cyclooxygenase-2 product prostaglandin E(2) in cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

21 January 2018

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

The role of COX-2 in intestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

The role of cyclooxygenases in inflammation, cancer, and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Upregulation of COX-2 during cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

Ischemia-reperfusion rapidly increases COX-2 expression in piglet cerebral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00136.2003

10.1152/AJPHEART.00136.2003

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference